{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:58:08Z","timestamp":1780556288716,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejmech.2022.114258","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T02:51:34Z","timestamp":1647571894000},"page":"114258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials"],"prefix":"10.1016","volume":"235","author":[{"given":"Hai","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7950-7669","authenticated-orcid":false,"given":"Di","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114258_bib1","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1016\/S0021-9258(18)98774-0","article-title":"TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase\/cyclooxygenase homologue","volume":"266","author":"Kujubu","year":"1991","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114258_bib2","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1073\/pnas.88.7.2692","article-title":"Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing","volume":"88","author":"Xie","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2022.114258_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2022.114258_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/bj3050479","article-title":"Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase","volume":"305","author":"Gierse","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.114258_bib5","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1248\/bpb.28.2075","article-title":"Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites","volume":"28","author":"Noguchi","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2022.114258_bib6","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2022.114258_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"VIGOR Study Group, N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114258_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114258_bib9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1191\/0961203305lu2221oa","article-title":"Cardiovascular effects of coxibs","volume":"14","author":"Caporali","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.ejmech.2022.114258_bib10","first-page":"617","article-title":"Cardiovascular effects of cyclooxygenase-2 inhibitors","volume":"23","author":"Brophy","year":"2007","journal-title":"Curr. Opin. Gastroenterol."},{"key":"10.1016\/j.ejmech.2022.114258_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","article-title":"Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective","volume":"82","author":"Patrono","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114258_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1586\/14779072.2.2.265","article-title":"Cardiovascular effects of selective cyclooxygenase-2 inhibitors","volume":"2","author":"Krum","year":"2004","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.ejmech.2022.114258_bib13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2165\/11209470-000000000-00000","article-title":"Intravenous ibuprofen: in adults for pain and fever","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2022.114258_bib14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.tetasy.2011.06.019","article-title":"Asymmetric synthesis of the active form of loxoprofen and its analogue","volume":"22","author":"Bhuniya","year":"2011","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.ejmech.2022.114258_bib15","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/jps.20451","article-title":"Comparison of pharmacokinetics of loxoprofen and its active metabolites after an intravenous, intramuscular, and oral administration of loxoprofen in rats: evidence for extrahepatic metabolism","volume":"94","author":"Koo","year":"2005","journal-title":"J.\u00a0Pharm. Sci.-Us"},{"key":"10.1016\/j.ejmech.2022.114258_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.bmcl.2003.12.047","article-title":"Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2","volume":"14","author":"Riendeau","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.114258_bib17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ddr.21314","article-title":"Topical anti-inflammatory and analgesic effects of multiple applications of S(+)-Flurbiprofen plaster (SFPP) in a rat adjuvant-induced arthritis model","volume":"77","author":"Sugimoto","year":"2016","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2022.114258_bib18","first-page":"862","article-title":"An efficient synthesis of (2S)-2-[4-((1R, 2S)-2-hydroxycyclopentylmethyl)phenyl]propionic acid","volume":"6","author":"Mandai","year":"2000","journal-title":"Synlett"},{"key":"10.1016\/j.ejmech.2022.114258_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0040-4039(97)10705-5","article-title":"Lipase-mediated diastereoselective and enantioselective acetylations of 3-substituted cyclohexanols","volume":"39","author":"Tanikaga","year":"1998","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.ejmech.2022.114258_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tetasy.2012.11.011","article-title":"Enzymatic preparation of (1S,2R)- and (1R,2S)-stereoisomers of 2-halocycloalkanols","volume":"24","author":"Kolodiazhna","year":"2013","journal-title":"Tetrahedron Asymmetry"},{"key":"10.1016\/j.ejmech.2022.114258_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00003088-200038050-00001","article-title":"Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach","volume":"38","author":"Davies","year":"2000","journal-title":"Clin. Pharmacokinet."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:38:46Z","timestamp":1759329526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342200160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"alternative-id":["S022352342200160X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114258","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HR1405-01, a Safe intravenous NSAID with superior anti-inflammatory and analgesic activities in preclinical trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114258"}}